Merck & Co (MRK)

The company could enter a fresh growth phase.

There is probably no dividend cut on the horizon for these healthcare companies.

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

SHCD is missing some of the healthiest dividend stocks.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

Investors buying this biotech stock now will get its pipeline essentially for free.

Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% in...

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Long-term holders of the Schwab U.S. Dividend Equity ETF have seen their yield on cost gradually rise.